Cardiology

An analysis of data from a pair of major trials indicates use of semaglutide was associated with a reduction in MACE regardless of a patient's baseline triglyceride levels.

The lipid profile changes were not significant after 6 months, while the changes in the lipid profile are due to other factors and not the drugs.

The AI-based technology is expected to augment telehealth and remote services for a vast majority of cardiological cases.

An analysis of cardiovascular outcomes from FIDELIO-DKD suggest finerenone use was associated with a 14% reduction in negative cardiovascular outcomes.

Ongoing debates question whether or not lipid lowering in elderly patients offers similar clinical benefit as in younger patients.

In a recent column Gregory Weiss, MD, uses studies from AHA Scientific Sessions 2020 to compare the cost-effectiveness of antihyperglycemic agents for reducing cardiovascular events.

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

Lonafarnib was linked to improved mortality over a maximum of 11 years follow-up, according to supporting data.

Dr. Gregory Weiss reflects on data related to bariatric surgery and its subsequent impact on cardiovascular health.

An analysis of CDC data presented at AHA Scientific Sessions 2020 suggests rates of high blood pressure complications among pregnant women nearly doubled during a period lasting from 2008-2017.

An analysis from AHA 2020 suggests an HbA1c screening protocol doubled the proportion of patients with known dysglycemia when treating patients with ST-elevation myocardial infarction.

Gregory Weiss, MD, examines 4 studies presented at AHA Scientific Sessions 2020 comparing the cost-effectiveness of antidiabetic agents for reducing cardiovascular events.

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

George Bakris, MD, discusses a study he took part in from AHA 2020 examining the number of diabetic patients meeting the American Diabetes Association's criteria for prescribing an SGLT2 inhibitor.

In data from several studies presented at AHA 2020, investigators tout bempedoic acid in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia.

Deepak Bhatt, MD, MPH, offers his thoughts on the most important REDUCE-IT analyses released in 2020 and why he disagrees with the notion results of the STRENGTH trial somehow impact the use of icosapent ethyl in clinical settings.

Data from a pair of phase 3 trials detail the effects of sotagliflozin in patients with type 2 diabetes and other comorbidities, such as worsening heart failure and chronic kidney disease.

George Bakris, MD, offers further insight into the cardiovascular outcomes analysis of FIDELIO-DKD presented at AHA 2020.

Data from a phase 2 trial suggests evinacumab, in both subcutaneous and intravenous doses, were effective at lowering LDL-C in patients with refractory hypercholesterolemia.

Results of the EARLY-AF study suggest first-line ablation may be a better approach for patients with symptomatic atrial fibrillation than first-line antiarrhythmic drugs.

Pooled analysis of SUSTAIN 6 and PIONEER 6 trials indicates the impact of semaglutide impact on MACE was present regardless of baseline triglyceride levels among diabetic patients.

Professor John McMurray explains why he is not as displeased as some colleagues are with the uptake of SGLT2 inhibitor prescribing rates for patients with heart failure or chronic kidney disease.

Data from HARP-MINOCA suggests use of OCT and cardiac CMR could help determine cause of symptoms in women presenting with MINOCA.

Results of the RIVER trial suggest rivaroxaban was noninferior to warfarin for the study's composite endpoint of all-cause mortality, major cardiovascular events, and major bleeding.

Results of the STRENGTH trial indicate treatment with 4 grams of omega-3 CA (Epanova) daily did not reduce risk of major adverse cardiovascular events and increased risk for atrial fibrillation and adverse events.

In data presented at AAO, investigators examine the impact of anti-VEGF injections on ocular hypertension.

In data presented at AAO 2020, researchers discover new methods for detecting different underlying conditions.

Presented at AHA 2020, results of GALACTIC-HF suggest omecamtiv mecarbil was associated with an 8% reduction in risk for worsening heart failure.

An analysis of blood samples from more than 19k women offers greater insight into the relationship between premature menopause and cardiovascular disease risk in postmenopausal women.

With the spotlight on the issue shining greater than ever in the US, the American Heart Association and cardiologists have been taking aim at addressing structural racism and its impact on health care.